Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Completed · Phase 2 · Has a placebo group

Conditions studied: Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI

In brief

This study evaluated the safety and efficacy of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).

Key facts

Study ID
NCT03788434
Run by
Vedanta Biosciences, Inc.
People needed
79
Starts
2019-02-08
Expected to finish
2021-09-15
Last updated by the study team
2023-07-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.